2minutemedicine.com1d
Different single inhaler triple therapies appear to have similar clinical outcomes for chronic obstructive pulmonary disease
In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...
Drug law will target costs, access, PBMs
Healey plans to host a ceremony at 11 a.m. Wednesday with legislative leaders to sign both the prescription drug bill and a ...
framinghamsource1d
Rep Lewis Joins on Legislation to Boost Oversight and Lower Drug Costs
Bill includes oversight reforms to improve affordability of and access to prescription drugs (Framingham—01/07/2025)—On New Year’s Eve the Massachusetts Legislature passed comprehensive reforms to ...
ENDPOINTS NEWS1d
Drug­mak­ers cut some list prices, shrink­ing room for re­bates in can­cer, asth­ma and di­a­betes
Bayer’s Nexavar and Boehringer Ingelheim's Spiriva are among a handful of drugs with reduced US list prices for the new year, ...
Daily Hampshire Gazette5d
New law set to rein in drug costs for many in Mass.
Around 200,000 Massachusetts residents with heart disease, asthma and diabetes will immediately benefit from lower ...
Doctor reveals common medications that can lead to a heart attack
Dr Zain Hasan is an anesthesiologist based out of California. He says everything from pain killers to chemo drugs could ...
WBUR8d
Legislature sends Healey bill targeting drug costs, oversight
Patients would pay no more than $25 for certain name-brand medications to treat chronic illnesses, including insulin for ...
Bill to limit out-of-pocket costs for chronic illness drugs sent to Gov. Healey
The bill would add scrutiny to pharmacy benefit managers and eliminate or cap out-of-pocket costs for drugs that treat ...
MM&M9d
2024’s most memorable pharma campaigns
From public campaigns featuring Cyndi Lauper to ads with dinosaurs, MM+M compiles the best public marketing campaigns from ...
Takeda Announces Approval of HYQVIA® 10% S.C. (Subcutaneous) Injection Set in Japan for Patients with Agammaglobulinemia or Hypogammaglobulinemia
Approval Expands Takeda’s Portfolio of Differentiated Immunoglobulin Therapies and Reflects the Company’s Commitment to Bring High-Quality Plasma-Derived Therapies to Patients in Japan ...